- Home
- DGICB vs SLS Comparison
DGICB vs SLS Comparison
Compare DGICB & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DGICB | SLS |
|---|---|---|
| Founded | 1986 | 2012 |
| Country | United States | United States |
| Employees | 851 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 654.6M | 706.7M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | DGICB | SLS |
|---|---|---|
| Price | $18.88 | $4.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 1.7K | ★ 4.9M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.60% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.26 | N/A |
| Revenue Next Year | N/A | $110.98 |
| P/E Ratio | $8.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.84 | $1.35 |
| 52 Week High | $20.30 | $6.14 |
Technical Indicators
Market Signals| Indicator | DGICB | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 59.79 | 43.82 |
| Support Level | $15.57 | $3.95 |
| Resistance Level | $19.34 | $5.18 |
| Average True Range (ATR) | 0.79 | 0.29 |
| MACD | 0.13 | -0.02 |
| Stochastic Oscillator | 76.90 | 18.95 |
Price Performance
Historical ComparisonAbout DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.